等待开盘 11-18 09:30:00 美东时间
-0.063
-7.79%
11月17日,Allogene Therapeutics(ALLO)收跌3.78%,报0.81美元,成交额691.36万美元,市值2.8亿美元。 行情数据 •...
11-17 07:26
11月10日,Allogene Therapeutics(ALLO)收涨1.92%,报1.06美元,成交额1127.43万美元,市值3.66亿美元。 行情数据...
11-10 07:18
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for cancer and autoimmune disease, today announced preliminary safety, efficacy and translational data from the ongoing Phase 1 RESOLUTION study eval...
11-09 21:05
Allogene Therapeutics (NASDAQ:ALLO) reported third-quarter financial results on Thursday. The transcript from the company’s third-quarter earnings call has been provided below. This transcript is brought to you by Benzinga APIs. For real-time access to our entire catalog, please visit https://www.be...
11-06 06:58
11月3日,Allogene Therapeutics(ALLO)收跌7.63%,报1.09美元,成交额1109.93万美元,市值3.77亿美元。 行情数据 ...
11-03 07:14
Theriva Biologics sold its portfolio of antibiotic-degrading enzymes, including SYN-004 (ribaxamase), SYN-007, and SYN-006, to Biossil Labs for $350,000 upfront, with potential milestone payments of up to $91 million and low single-digit royalties. Biossil will handle future development and commercialization. The deal aims to advance clinical trials targeting prevention of infections like C. difficile and aGVHD in transplant patients.
11-02 13:00
Allogene Therapeutics will participate in three upcoming investor conferences in November and December 2026: the UBS Global Biopharma Conference on November 16 in London, the Jefferies Global Healthcare Conference on November 18 in London, and the Piper Sandler 38th Annual Healthcare Conference on December 2 in New York. Webcasts and replays will be available on the company’s website. Allogene is a clinical-stage biotech company developing alloge...
10-26 12:30
10月24日,Allogene Therapeutics(ALLO)收平,报1.25美元,成交额1007.64万美元,市值4.32亿美元。 行情数据 • 开盘价...
10-24 06:14
10月20-22日上海黄浦江畔,2026可持续全球领导者大会再度来袭。诺奖、图灵奖得主现场讲述科技未来与趋势,更有“解救”焦虑、内卷时代的网红教授——麦克法兰与...
10-17 06:12
CRISPR Therapeutics announced that it will present Phase 1 clinical data for its investigational CRISPR/Cas9 gene-edited allogeneic CAR T cell therapy, zugocabtagene geleucel (zugo-cel), targeting CD19 for autoimmune diseases, at the American College of Rheumatology (ACR) Convergence 2026. The poster presentation, titled "Safety and Efficacy of Anti-CD19 Allogeneic Chimeric Antigen Receptor (CAR) T Cell Therapy Zugocabtagene Geleucel (zugo-cel) i...
10-02 14:15